Drugmakers took big hits last year on failed clinical trials

02/6/2013 | Genetic Engineering & Biotechnology News

The suspension of a Phase IIb trial of Bristol-Myers Squibb's BMS-986094 nucleotide polymerase inhibitor resulted in a $1.8 billion write-off. Other expensive failures include a joint Pfizer-Johnson & Johnson candidate for Alzheimer's disease, an AstraZeneca and Targacept adjunct to antidepressant treatment, and an Eli Lilly & Co. schizophrenia drug.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ